Reading GDRX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track GDRX free→Reading GDRX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track GDRX free→QuarterlyIQ Insights · GDRX
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Chief Accounting Officer Appointment On April 23, 2026, the Board of Directors (the “Board”) of GoodRx Holdings, Inc. (the “Company”) appointed Thomas Chan, Vice President, Corporate Controller of the Company as the Company’s Chief Accounting Officer and designated Mr. Chan as the principal accounting officer of the Company, in each case effective…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Director On March 31, 2026, Ian T. Clark notified GoodRx Holdings, Inc. (the “Company”) of his decision to resign as a member of the Company’s Board of Directors (the “Board“), including his service on the Board’s Nominating & Governance Committee, effective as of March 31, 2026. Mr. Clark has indicated to the Company that his decision…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Chief Accounting Officer Resignation On March 24, 2026, Romin Nabiey submitted his resignation as Chief Accounting Officer of GoodRx Holdings, Inc. (the “Company”), effective April 3, 2026 in order to pursue other opportunities. Mr. Nabiey will remain an employee of the Company through June 8, 2026 to support the transition of his responsibilities…
Changes in Registrant’s Certifying Accountant On March 14, 2026, the Audit and Risk Committee of the Board of Directors of GoodRx Holdings, Inc. (the “Company”), following a competitive proposal process, approved the appointment of KPMG LLP (“KPMG”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved the dismissal of PricewaterhouseCoopers LLP (“PwC”) as the Company’s independent registered public accounting firm. The audit…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Compensatory Arrangements of Certain Executive Officers On March 3, 2026, the Board of Directors (the “Board”) of GoodRx Holdings, Inc. (the “Company”), upon the recommendation of the Compensation Committee of the Board approved a discretionary cash bonus for 2025 performance in the amount of $72,918 for Romin Nabiey, the Company’s Chief Accounting…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Director On February 26, 2026, Dipanjan Deb notified GoodRx Holdings, Inc. (the “Company”) of his decision to resign as a member of the Company’s Board of Directors, effective as of February 26, 2026. Mr. Deb has indicated to the Company that his decision to resign is not the result of any disagreement with the Company or its managemen…
and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 9, 2025, the Board of Directors of GoodRx Holdings, Inc. (the “Company”) approved the entry by GoodRx, Inc. (a subsidiary of the Company) into retention bonus letter agreements (the “Retention Bonus Agreements”) with each of Wendy Barnes, Chief Executive Officer and President of the Company, and Chris McGinnis, Chief Financial Officer a…
and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 31, 2025, GoodRx Holdings, Inc. (the “Company”) and Trevor Bezdek, the Company’s Co-Chairman of the Board of Directors (the “Board”), mutually agreed to end Mr. Bezdek’s employment and executive officer service with the Company and its subsidiaries upon the expiration of his employment agreement on November 1, 2025. Mr. Bezdek will conti…
and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Other Events On March 16, 2025 (the “Effective Date”), GoodRx Holdings, Inc. (the “Company”) entered into three Stock Purchase Agreements: (a) one with Spectrum Equity VII, L.P., Spectrum VII Investment Managers’ Fund, L.P., and Spectrum VII Co-Investment Fund, L.P. (collectively, “Spectrum”), (b) one with Francisco Partners IV, L.P. and Francisco Partners IV-A (collectively, “Francisco Partners”) and (c) one with Idea Men, LLC (“Idea Men”). Pursuant to such agreements, the Company agreed to…
and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Chief Financial Officer and Treasurer Appointment On February 4, 2025, the Board of Directors (the “Board”) of GoodRx Holdings, Inc. (the “Company”) appointed Christopher A. McGinnis as Chief Financial Officer and Treasurer of the Company, effective as of his commencement of employment, which occurred on February 4, 2025 (the “Effective Date”). Mr.…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 21, 2025, the Board of Directors (the “Board”) of GoodRx Holdings, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, appointed Scott Wagner as a Class II director of the Company. Mr. Wagner’s term will expire at the Company’s 2025 Annual Meeting of Stockholders and until his successor is…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.